Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular … – Nature.com

Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:20018.

Article CAS PubMed Google Scholar

Vollenweider FX, Smallridge JW. Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry. 2022;55:12138.

Article PubMed PubMed Central Google Scholar

Lpez-Gimnez JF, Gonzlez-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45.

Article PubMed PubMed Central Google Scholar

Mendes FR, dos Santos Costa C, Wiltenburg VD, Morales-Lima G, Fernandes JAB, Filev R. Classic and nonclassic psychedelics for substance use disorder: a review of their historic, past and current research. Addict Neurosci. 2022;3:100025.

Article Google Scholar

Dai R, Larkin TE, Huang Z, Tarnal V, Picton P, Vlisides PE, et al. Classical and non-classical psychedelic drugs induce common network changes in human cortex. Neuroimage. 2023;273:120097.

Article PubMed Google Scholar

Inserra A. Hypothesis: the psychedelic ayahuasca Heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process. Front Pharmacol. 2018;9:330.

Article PubMed PubMed Central Google Scholar

Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:15566.

Article PubMed Google Scholar

Glintborg C, Thomsen AS, Hansen TGB. Beyond broken bodies and brains: a mixed methods study of mental health and life transitions after brain injury. Brain Impairment. 2018;19:21527.

Article Google Scholar

Hiplito I, Mago J, Rosas FE, Carhart-Harris R. Pattern breaking: a complex systems approach to psychedelic medicine. PsyArXiv. https://doi.org/10.31234/OSF.IO/YDU3H (2023).

Goodwin GM, Aaronson ST, Dunlop BW, Feifel D, Hellerstein DJ, Hewitt N, et al. The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial. Neurosci Appl. 2022;1:100511.

Article Google Scholar

Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord. 2019;258:1124.

Article PubMed Google Scholar

Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23:385.

Article CAS PubMed PubMed Central Google Scholar

Johnson MW. Classic psychedelics in addiction treatment: the case for psilocybin in tobacco smoking cessation. Curr Top Behav Neurosci. 2022;56:21327.

Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:173540.

Article CAS PubMed Google Scholar

Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models. Front Neurosci. 2020;14:43.

Article PubMed PubMed Central Google Scholar

Zeifman RJ, Singhal N, dos Santos RG, Sanches RF, de Lima Osrio F, Hallak JEC, et al. Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology. 2021;238:4539.

Article CAS PubMed Google Scholar

Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA. Ketamine and serotonergic psychedelics: an update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology. 2023;226:109422.

Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Appl Mater Interfaces. 2020. https://doi.org/10.1021/ACSCHEMNEURO.9B00493/SUPPL_FILE/CN9B00493_LIVESLIDES.MP4.

Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022. https://doi.org/10.1001/JAMAPSYCHIATRY.2022.2096.

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399408.

Article CAS PubMed Google Scholar

Magaraggia I, Kuiperes Z, Schreiber R. Improving cognitive functioning in major depressive disorder with psychedelics: a dimensional approach. Neurobiol Learn Mem. 2021;183:107467.

Article CAS PubMed Google Scholar

Sayal C, Barrett FS. The costs and benefits of psychedelics on cognition and mood. Neuron 2023;111:61430.

Article PubMed Google Scholar

Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The therapeutic potential of psilocybin. Molecules. 2021;26:2948.

Article CAS PubMed PubMed Central Google Scholar

Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:102533.

Article CAS PubMed PubMed Central Google Scholar

Berger JJ, Fitzgerald PB. The prescription of psychedelic therapies in Australia and New Zealand: a brief survey of psychiatrists. Australas Psychiatry. 2023;31:190.

Article PubMed PubMed Central Google Scholar

Grover C, Monds L, Montebello M. A survey of Australian psychiatrists and psychiatry trainees knowledge of and attitudes towards psychedelics in the treatment of psychiatric disorders. Australas Psychiatry. 2023;31:32935.

Article PubMed Google Scholar

Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30:36375.

Article PubMed Google Scholar

Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol Lett. 2020;228:4554.

Article CAS PubMed Google Scholar

de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021;12:1575.

Google Scholar

Ly C, Greb AC, Vargas MV, Duim WC, Grodzki ACG, Lein PJ, et al. Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacol Transl Sci. 2021;4:45260.

Article CAS PubMed Google Scholar

Arciniegas DB. Addressing neuropsychiatric disturbances during rehabilitation after traumatic brain injury: current and future methods. 2022;13:32545. https://doi.org/10.31887/DCNS2011132/darciniegas.

Bramlett HM, Dietrich WD. Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma. 2015;32:1834.

Article PubMed PubMed Central Google Scholar

Khan SM, Carter GT, Aggarwal SK, Holland J. Psychedelics for brain injury: a mini-review. Front Neurol. 2021;12:1260.

Article Google Scholar

Mallah K, Couch C, Borucki DM, Toutonji A, Alshareef M, Tomlinson S. Anti-inflammatory and neuroprotective agents in clinical trials for CNS disease and injury: where do we go from here? Front Immunol. 2020;11:2021.

Article CAS PubMed PubMed Central Google Scholar

Feigin VL, Barker-Collo S, Krishnamurthi R, Theadom A, Starkey N. Epidemiology of ischaemic stroke and traumatic brain injury. Best Pract Res Clin Anaesthesiol. 2010;24:48594.

Article PubMed Google Scholar

Xu XJ, Yang MS, Zhang B, Niu F, Dong JQ, Liu BY. Glucose metabolism: a link between traumatic brain injury and Alzheimers disease. Chin J Traumatol. 2021;24:5.

Article PubMed Google Scholar

Lu J, Goldman L, Siddiqui EM, Khan A, Jahan S, Rehman MU, et al. Understanding acquired brain injury: a review. Biomedicines. 2022;10:2167.

Article Google Scholar

Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018;130:108097.

Article PubMed Google Scholar

Voss JD, Connolly J, Schwab KA, Scher AI. Update on the epidemiology of concussion/mild traumatic brain injury. Curr Pain Headache Rep. 2015;19:18.

Article Google Scholar

Donkor ES. Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018;2018:3238165.

Strilciuc S, Grad DA, Radu C, Chira D, Stan A, Ungureanu M, et al. The economic burden of stroke: a systematic review of cost of illness studies. J Med Life. 2021;14:606.

Article PubMed PubMed Central Google Scholar

Lund SB, Gjeilo KHKH, Moen KG, Schirmer-Mikalsen K, Skandsen T, Vik A. Moderate traumatic brain injury, acute phase course and deviations in physiological variables: an observational study. Scand J Trauma Resusc Emerg Med. 2016;24:18.

Article Google Scholar

Schimmel S, Acosta S, Lozano D. Neuroinflammation in traumatic brain injury: a chronic response to an acute injury. Brain Circ. 2017;3:135.

Article PubMed PubMed Central Google Scholar

Chugh C. Acute ischemic stroke: management approach. Indian J Crit Care Med. 2019;23:S140.

Article PubMed PubMed Central Google Scholar

Ponsford J, Nguyen S, Downing M, Bosch M, McKenzie JE, Turner S, et al. Factors associated with persistent post-concussion symptoms following mild traumatic brain injury in adults. J Rehabil Med. 2019;51:3239.

Article PubMed Google Scholar

Nelson LD, Temkin NR, Dikmen S, Barber J, Giacino JT, Yuh E, et al. Recovery after mild traumatic brain injury in patients presenting to US level I trauma centers: a transforming research and clinical knowledge in traumatic brain injury (TRACK-TBI) study. JAMA Neurol. 2019;76:104959.

Article PubMed PubMed Central Google Scholar

Lee B, Bennett LL, Bernick C, Shan G, Banks SJ. The relations among depression, cognition, and brain volume in professional boxers: a preliminary examination using brief clinical measures. J Head Trauma Rehabil. 2019;34:E29E39.

Article PubMed Google Scholar

Major B, Symons GF, Sinclair B, OBrien WT, Costello D, Wright DK, et al. White and gray matter abnormalities in Australian footballers with a history of sports-related concussion: an MRI study. Cereb Cortex. 2021;31:53318.

Article PubMed Google Scholar

Wright DK, Symons GF, OBrien WT, McDonald SJ, Zamani A, Major B, et al. Diffusion imaging reveals sex differences in the white matter following sports-related concussion. Cereb Cortex. 2021;31:44119.

Article PubMed Google Scholar

Costello K, Greenwald BD. Update on domestic violence and traumatic brain injury: a narrative review. Brain Sci. 2022;12:122.

Mans K, Kettner H, Erritzoe D, Haijen ECHM, Kaelen M, Carhart-Harris RL. Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample. Front Psychiatry. 2021;12:1038.

Article Google Scholar

Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 2018;235:535.

Article CAS PubMed Google Scholar

Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014;9:101725.

Article PubMed Google Scholar

Ayerbe L, Ayis S, Wolfe CDA, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202:1421.

Article PubMed Google Scholar

View post:

Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com